Vir Biotechnology, Inc. Expense Breakdown
No Expense Breakdown for VIR on this site yet.
- 2026-06-30: Reportable $0.00.
- 2025-06-30: Reportable $11.00K.
Source checked: the stored Expense Breakdown page for VIR.
Expenses by product
Cost of sales: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $0.00 |
| 2025-06-30 | $11.00K |
Selling, General and Administrative Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $30.20M |
| 2025-06-30 | $22.28M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |